3-(4-isopropyl-piperazin-1-yl)-6-(4-methanesulfonyl-phenyl)-pyridazine | 577966-75-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-(4-isopropyl-piperazin-1-yl)-6-(4-methanesulfonyl-phenyl)-pyridazine
• 英文别名: 3-(4-methylsulfonylphenyl)-6-(4-propan-2-ylpiperazin-1-yl)pyridazine
• CAS: 577966-75-7
• 化学式: C₁₈H₂₄N₄O₂S
• 分子量: 360.48
• InChiKey: LGFBOGQSUJXACU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  74.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-异丙基哌嗪 、 3-Chloro-6-[4-(methanesulfonyl)phenyl]pyridazine 生成 3-(4-isopropyl-piperazin-1-yl)-6-(4-methanesulfonyl-phenyl)-pyridazine
  参考文献：
  名称：

  Novel aryl- and heteroarylpiperazines

  摘要：

  小说芳基和杂环芳基哌嗪，这些化合物的药物组成物的使用，包含这些化合物的药物组成物，以及使用这些化合物和组成物的治疗方法。这些化合物显示出高度和选择性的结合亲和力，表明组胺H3受体拮抗，反向激动剂或激动剂活性。因此，这些化合物对于治疗与组胺H3受体相关的疾病和障碍非常有用。

  公开号：

  US20030236259A1

文献信息

• Novel Aryl- and Heteroarylpiperazines
  申请人：Hohlweg Rolf

  公开号：US20090264435A1

  公开（公告）日：2009-10-22

  Novel aryl- and heteroarylpiperazines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.

  新型芳基和杂环基哌嗪，这些化合物的药用组合物，包含这些化合物的药用组合物，以及采用这些化合物和组合物的治疗方法。这些化合物表现出高度和选择性的结合亲和力，表明它们具有组胺H3受体拮抗、反向激动或激动活性。因此，这些化合物对于治疗与组胺H3受体相关的疾病和障碍非常有用。
• NOVEL ARYL- AND HETEROARYLPIPERAZINES
  申请人：NOVO NORDISK A/S

  公开号：EP1474401A2

  公开（公告）日：2004-11-10
• QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS
  申请人：Amgen Inc.

  公开号：EP1478645A2

  公开（公告）日：2004-11-24
• [EN] COMPOUNDS AND METHODS OF USES<br/>[FR] COMPOSES ET PROCEDES D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2003066630A2

  公开（公告）日：2003-08-14

  Selected compounds of formula (I) wherein (a) is (b) or (c) wherein A is O, S or NH; wherein D is CR1 or N; wherein E is CR2 or N; wherein F is CR3 or N; wherein F is CR4 or N; wherein J is selected from NR6, S, O, and CR1 wherein K is selected from NR6 , S, O, and CR2; wherein L is selected from NR6, S, O, and CR3 are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
• [EN] NOVEL ARYL- AND HETEROARYLPIPERAZINES<br/>[FR] NOUVELLES ARYL- ET HETEROARYLPIPERAZINES
  申请人：NOVO NORDISK AS

  公开号：WO2003066604A2

  公开（公告）日：2003-08-14

  Novel aryl- and heteroarylpiperazines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.